TB Alliance

In April 2016, we signed a MoU with TB Alliance outlining a multi-pronged collaboration to encourage the development of new TB regimens and to ensure their availability in LMICs.

In October 2017, MPP and TB Alliance signed a second MoU to facilitate third-party development of sutezolid-containing TB regimens. The MoU followed theĀ sublicensing agreementĀ signed by both organisations in March 2017 granting TB Alliance the rights to develop the treatment for drug-susceptible and drug-resistant TB patients.